María Asunción Echeveste

Learn More
BACKGROUND GP2013 is a rituximab biosimilar developed to stringent development guidelines, including non-clinical and preclinical investigations and clinical trials in rheumatoid arthritis and follicular lymphoma. We aimed to compare the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of GP2013 plus cyclophosphamide, vincristine, and(More)
Bendamustine is a bifunctional alkylating agent with proven activity in myeloma. In this study 60 newly diagnosed myeloma patients were given bendamustine plus bortezomib and prednisone in a regimen consisting of one cycle of bortezomib twice weekly for 6 weeks (1.3 mg/m(2) on days 1, 4, 8, 11, 22, 25, 29, and 32), plus bendamustine (90 mg/m(2) on days 1(More)
A retrospective study was performed of 33 cases of non Hodgkin's lymphoma in children diagnosed in our hospital. The mean age was 10 years and there were 24 males and 9 females. The distribution, according to Rappaport's diagnostic classification, was: 11 undifferentiated lymphomas, 9 lymphoblastic lymphomas, 6 diffuse histiocytic lymphomas, and 7 cases of(More)
  • 1